115,494 Shares in uniQure N.V. $QURE Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. acquired a new position in uniQure N.V. (NASDAQ:QURE) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 115,494 shares of the biotechnology company’s stock, valued at approximately $2,764,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in QURE. Woodline Partners LP grew its holdings in uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares in the last quarter. Legal & General Group Plc bought a new position in uniQure in the 2nd quarter worth approximately $497,000. Marshall Wace LLP grew its holdings in uniQure by 276.5% in the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after buying an additional 163,749 shares in the last quarter. California State Teachers Retirement System bought a new position in uniQure in the 2nd quarter worth approximately $540,000. Finally, Ameriprise Financial Inc. grew its holdings in uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

QURE has been the subject of a number of research reports. Mizuho raised uniQure from a “neutral” rating to an “outperform” rating and increased their price target for the company from $12.00 to $35.00 in a research note on Wednesday, March 11th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Leerink Partners reaffirmed an “outperform” rating and set a $35.00 price target on shares of uniQure in a research note on Monday, March 2nd. Finally, Stifel Nicolaus set a $28.00 price target on uniQure in a research note on Tuesday. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and a consensus price target of $42.83.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $27.66 on Friday. The stock has a fifty day moving average price of $16.67 and a two-hundred day moving average price of $24.73. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.43 and a current ratio of 10.40. The firm has a market cap of $1.74 billion, a P/E ratio of -7.95 and a beta of 0.87. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. Research analysts forecast that uniQure N.V. will post -3.68 EPS for the current fiscal year.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and $50 price target on uniQure while nudging near-term earnings estimates higher for Q2 and Q3 2026, which can support sentiment by signaling slightly better-than-expected operating performance.
• Positive Sentiment: Investors also appear encouraged by reports that uniQure plans a UK AMT-130 MAA submission in Q3 and expects its cash runway into H2 2029, reducing near-term financing concerns and highlighting progress for its pipeline.
• Neutral Sentiment: HC Wainwright made mixed long-range forecast changes, including higher FY2027 estimates but lower FY2028, FY2029, and FY2030 EPS expectations, suggesting a more uneven long-term outlook rather than a broad upgrade.
• Negative Sentiment: The updated analyst estimates still show uniQure remaining deeply unprofitable across the forecast period, so the stock could face pressure if clinical progress or commercialization timelines slip.

Insider Transactions at uniQure

In other news, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the sale, the insider directly owned 138,483 shares of the company’s stock, valued at $1,254,655.98. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $132,103.86. Following the sale, the chief executive officer directly owned 660,658 shares of the company’s stock, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 49,396 shares of company stock valued at $722,734 in the last three months. 4.79% of the stock is currently owned by corporate insiders.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.